U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions ...

A genetic disorder, Huntington’s leads to the breakdown of nerves and a progressive inability to think, move and function. No treatment has so far been approved to slow the condition’s march, although ...

Eplontersen’s study was among the most eagerly anticipated readouts in the biopharmaceutical sector this year. Success would yield a substantial market opportunity and was largely expected by industry ...

A collaboration between GSK and the California-based biotechnology company Alector has fizzled following major setbacks for the experimental brain drugs at the center of the deal. The companies first ...

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side ...

The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of ...

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...

The Food and Drug Administration has cleared a new treatment from Vera Therapeutics in the latest step forward for an emerging class of medications that have shown the ability to combat a rare and ...

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC ...